Posted by Michael Wonder on 24 Jul 2019
FDA seeks input on biomarker, endpoint glossary
24 July 2019 - Two-and-a-half years after its release, the US FDA is asking for input from the public on the utility of its Biomarkers, EndpointS, and other Tools (BEST) glossary as it looks to refine the resource going forward.
“Today we are seeking public comment on this resource to help determine its utility, develop future iterations and best identify methods for conveying this information.
Ultimately, we hope that this glossary will help in accelerating drug development and improving health outcomes for patients,” said FDA Principal Deputy Commissioner Amy Abernethy.
